Sanofi has started reevaluation negotiations for its atopic dermatitis treatment ‘Dupixent,' which has been receiving reimbursement under the RSA (Risk Sharing Agreement).

According to industry sources, Dupixent’s RSA term ends on December 31st, therefore, the drug is undergoing reevaluation negotiations with the National Health Insurance Service. In other words, the company needs to renew the RSA contract within the year to allow the drug to be applied for reimbursement without any issue.

Of course, no company has failed to renew its RSA until now. However, the mechanism of the RSA makes it so that every time a reevaluation is conducted, the price is further reduced, raising tensions